| pubmed-article:7743483 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7743483 | lifeskim:mentions | umls-concept:C0153633 | lld:lifeskim |
| pubmed-article:7743483 | lifeskim:mentions | umls-concept:C0021270 | lld:lifeskim |
| pubmed-article:7743483 | lifeskim:mentions | umls-concept:C0728836 | lld:lifeskim |
| pubmed-article:7743483 | lifeskim:mentions | umls-concept:C0039871 | lld:lifeskim |
| pubmed-article:7743483 | lifeskim:mentions | umls-concept:C0392920 | lld:lifeskim |
| pubmed-article:7743483 | lifeskim:mentions | umls-concept:C0220825 | lld:lifeskim |
| pubmed-article:7743483 | lifeskim:mentions | umls-concept:C0205390 | lld:lifeskim |
| pubmed-article:7743483 | lifeskim:mentions | umls-concept:C0332283 | lld:lifeskim |
| pubmed-article:7743483 | pubmed:issue | 11 | lld:pubmed |
| pubmed-article:7743483 | pubmed:dateCreated | 1995-6-15 | lld:pubmed |
| pubmed-article:7743483 | pubmed:abstractText | Chemotherapy may be used to delay the need for cranial irradiation in infants and young children with malignant central nervous system (CNS) tumors. The polyfunctional alkylator thiotepa (TT) possesses significant in vitro and in vivo activity in many central nervous system tumors. Before the introduction of a multiagent chemotherapy previously shown to be active in such tumors, thiotepa alone was evaluated in an upfront therapeutic window. | lld:pubmed |
| pubmed-article:7743483 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7743483 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7743483 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7743483 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:7743483 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7743483 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7743483 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7743483 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7743483 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7743483 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7743483 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:7743483 | pubmed:issn | 0008-543X | lld:pubmed |
| pubmed-article:7743483 | pubmed:author | pubmed-author:FriedmanH SHS | lld:pubmed |
| pubmed-article:7743483 | pubmed:author | pubmed-author:FOXJ PJP | lld:pubmed |
| pubmed-article:7743483 | pubmed:author | pubmed-author:HeidemanR LRL | lld:pubmed |
| pubmed-article:7743483 | pubmed:author | pubmed-author:JenkinsJ JJJ | lld:pubmed |
| pubmed-article:7743483 | pubmed:author | pubmed-author:HorowitzM EME | lld:pubmed |
| pubmed-article:7743483 | pubmed:author | pubmed-author:FaircloughD... | lld:pubmed |
| pubmed-article:7743483 | pubmed:author | pubmed-author:RazzoukB IBI | lld:pubmed |
| pubmed-article:7743483 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7743483 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:7743483 | pubmed:volume | 75 | lld:pubmed |
| pubmed-article:7743483 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7743483 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7743483 | pubmed:pagination | 2762-7 | lld:pubmed |
| pubmed-article:7743483 | pubmed:dateRevised | 2010-3-24 | lld:pubmed |
| pubmed-article:7743483 | pubmed:meshHeading | pubmed-meshheading:7743483-... | lld:pubmed |
| pubmed-article:7743483 | pubmed:meshHeading | pubmed-meshheading:7743483-... | lld:pubmed |
| pubmed-article:7743483 | pubmed:meshHeading | pubmed-meshheading:7743483-... | lld:pubmed |
| pubmed-article:7743483 | pubmed:meshHeading | pubmed-meshheading:7743483-... | lld:pubmed |
| pubmed-article:7743483 | pubmed:meshHeading | pubmed-meshheading:7743483-... | lld:pubmed |
| pubmed-article:7743483 | pubmed:meshHeading | pubmed-meshheading:7743483-... | lld:pubmed |
| pubmed-article:7743483 | pubmed:meshHeading | pubmed-meshheading:7743483-... | lld:pubmed |
| pubmed-article:7743483 | pubmed:meshHeading | pubmed-meshheading:7743483-... | lld:pubmed |
| pubmed-article:7743483 | pubmed:meshHeading | pubmed-meshheading:7743483-... | lld:pubmed |
| pubmed-article:7743483 | pubmed:meshHeading | pubmed-meshheading:7743483-... | lld:pubmed |
| pubmed-article:7743483 | pubmed:meshHeading | pubmed-meshheading:7743483-... | lld:pubmed |
| pubmed-article:7743483 | pubmed:meshHeading | pubmed-meshheading:7743483-... | lld:pubmed |
| pubmed-article:7743483 | pubmed:meshHeading | pubmed-meshheading:7743483-... | lld:pubmed |
| pubmed-article:7743483 | pubmed:meshHeading | pubmed-meshheading:7743483-... | lld:pubmed |
| pubmed-article:7743483 | pubmed:meshHeading | pubmed-meshheading:7743483-... | lld:pubmed |
| pubmed-article:7743483 | pubmed:year | 1995 | lld:pubmed |
| pubmed-article:7743483 | pubmed:articleTitle | A phase II evaluation of thiotepa followed by other multiagent chemotherapy regimens in infants and young children with malignant brain tumors. | lld:pubmed |
| pubmed-article:7743483 | pubmed:affiliation | Department of Hematology/Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee 38101, USA. | lld:pubmed |
| pubmed-article:7743483 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7743483 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:7743483 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:7743483 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:7743483 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:7743483 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7743483 | lld:pubmed |
